The potential for a generally applicable mapping model between QLQ-C30 and SF-6D in patients with different cancers: a comparison of regression-based methods.

Purpose: To establish and compare generalized or "global" mapping relationships between QLQ-C30 and SF-6D, applicable across different cancer types.Methods: Patients (N = 671) with breast, myeloma, colorectal, lymphoma, bone marrow, prostate, lung and gastroenteric cancer were randomly split into es...

Descripción completa

Detalles Bibliográficos
Publicado en:Quality of Life Research Vol. 24; no. 6; pp. 1535 - 1545
Autor principal: Kontodimopoulos, Nick
Formato: research Journal Article
Publicado: Springer Nature Jun2015
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109744293&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 109744293
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        09629343
        GPQ
      jtl: Quality of Life Research
      issn: 09629343
      maglogo: N
    pubinfo:
      dt: Jun2015
      vid: 24
      iid: 6
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        109744293
        NLM25391489
        2013040573
        10.1007/s11136-014-0857-7
        NLM25391489
        109744293
      ppf: 1535
      ppct: 10
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: The potential for a generally applicable mapping model between QLQ-C30 and SF-6D in patients with different cancers: a comparison of regression-based methods.
      aug:
        au: Kontodimopoulos, Nick
      sug:
      ab: Purpose: To establish and compare generalized or "global" mapping relationships between QLQ-C30 and SF-6D, applicable across different cancer types.Methods: Patients (N = 671) with breast, myeloma, colorectal, lymphoma, bone marrow, prostate, lung and gastroenteric cancer were randomly split into estimation (75%) and validation (25%) datasets. SF-6D was estimated from QLQ-C30 scores via ordinary least squares, generalized linear models and median (least-absolute deviations) regression approaches, and with Bayesian additive regression kernels. Predictive ability was assessed with root mean square error, mean absolute error and proportions of predictions with absolute errors >0.05 and >0.1, whereas explanatory power with adjusted R (2) or equivalent fit measures. Two external samples (breast and colorectal cancer) were used to further test the models.Results: The QLQ-C30's global health item, the physical, emotional and social functioning scales, and the fatigue, pain and diarrhea symptom scales were significant predictors (p < 0.05 or better) in all models. Negligible deviations in models' performance were observed. All models overpredicted utilities for patients in worst health and underpredicted them for those in better health (p < 0.01 or better). Regarding external validation, performance was better in the colorectal cancer than in the breast cancer sample.Conclusions: This study has provided evidence to support the use of "global" mapping models to predict SF-6D utilities from QLQ-C30 in patients with different cancers. Testing with diverse patient samples is required to confirm the generalizability (or not) of mapping models across cancer conditions.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N